SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on January 23, 2018, reporting events that occurred on January 21, 2018. The filing addresses corporate governance actions regarding the company's equity incentive plan and executive compensation. The filing text does not provide a clear value for the company's general business operations or reporting period beyond the specific event date.
Key Financial Metrics
The filing does not contain financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point provided is the stock price used to determine option exercise prices.
- Stock Price (Jan 19, 2018): $5.85 per share (closing price on NASDAQ Capital Market).
Material Changes and Corporate Actions
The Board of Directors unanimously approved an amendment to the 2017 Equity Incentive Plan (2017 EIP) to reserve an additional 500,000 shares of common stock. These shares are designated exclusively for grants to new hires as an inducement material to their entry into employment, pursuant to NASDAQ Rule 5635(c)(4). This amendment was executed without stockholder approval.
Concurrently, the Board approved stock option grants to three executive officers under the amended plan:
| Executive Name | Title | Options Granted | Exercise Price |
|---|---|---|---|
| Frank Jaksch | Chief Executive Officer | 50,000 | $5.85 |
| Robert Fried | President, COO, and Chief Strategy Officer | 300,000 | $5.85 |
| Troy Rhonemus | SVP and Chief Medical Officer | 120,000 | $5.85 |
Outlook, Risks, and Vesting Terms
The filing details specific vesting schedules and acceleration clauses for the granted options:
- Frank Jaksch: Four-year vesting schedule (25% after one year, monthly thereafter). Includes full acceleration upon resignation for good reason or termination without cause, subject to a separation agreement.
- Robert Fried: 83,333 shares vested immediately; remaining shares vest monthly over 26 months. Includes full acceleration upon change in control, death, disability, termination without cause, or resignation for good reason.
- Troy Rhonemus: Four-year vesting schedule. Includes full acceleration if a change in control occurs and employment is terminated without cause within a specific window surrounding the event.
The filing does not provide management commentary on future financial outlook, general risks, or contingencies beyond the terms of the equity grants.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2017 EIP post-amendment to assess potential dilution.
- Confirm the vesting commencement dates for the executive options to understand future expense recognition.
- Review the full text of Exhibit 99.1 (Amended 2017 EIP) for complete terms and conditions.
- Monitor future filings for the actual issuance of shares upon option exercises.